ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sotevtamab

Also written as “Sotevtamab” and “AB-16B5”.

Its studies are mostly in Pancreatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Neoplasm Metastasis, led by 2 companies.

Drug pageSotevtamab: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Apr 23, 20204 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alethia Biotherapeuticsits history only31 open or runningphase 2since Apr 23, 2020Mar 30, 2015none ahead
ImmunityBio10 open or runningphase 1since Nov 20, 2025Nov 20, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of ImmunityBio only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 28, 2021Named sotevtamabINNProposed as its International Nonproprietary Name in WHO's List 125
  2. Nov 20, 2025First study: phase 1 study in Pancreatic NeoplasmsFirst studyNCT07488884

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study ImmunityBio leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07488884Pancreatic Neoplasms1WithdrawnJun 1, 20270

How it is read

Names in the registry

  • “Sotevtamab”, 2 entries
  • “AB-16B5”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.